Clinics in Perinatology 1993: Vol 20 Index

19 Pages·1993·3.1 MB·English

CUMULATIVE INDEX 1993
Volume 20
March CURRENT CONTROVERSIES IN PERINATAL CARE II,
pages 1-285
June PERINATAL ASPHYXIA, pages 287-505
September DIABETES IN PREGNANCY, pages 507-667
December SURFACTANT REPLACEMENT THERAPY, pages 669-848
Note: Page numbers of issue and article titles are in boldface type.
Abortion, spontaneous, in diabetic Airway stabilization, surfactant in, 761-762
pregnancies, 537-538 Albumin excretion, in diabetic
Academic career, in neonatal medicine, 1-8 nephropathy, incipient, 562
basic science pathway in, 2-3 Alcohol abuse, in women, 31-32
clinical, 6-7 treatment of, 36-39
fellowship programs for, 3-4 ALEC (artificial lung expanding
motivation for, 2 compound), 818
paths for, 2 in respiratory distress syndrome (neona-
post fellowship programs for, 4 tal), 738-739
research support and, 4-6 Alkalosis, metabolic, induced, in
teaching in, 7 pulmonary hypertension, 136
training programs for, 2 Allopurinol, in cerebral hypoxia-ischemia,
Academic function, perinatal asphyxia 413-414
effects on, 490-491 Alpha adrenergic blocking agents, in
Acetoacetate, excessive, in diabetic hypertension, in diabetic nephropathy,
pregnancies, congenital anomalies and, 567
523 Alpha tocopherol, in cerebral hypoxia-
Acidemia, in perinatal asphyxia, 290-293, ischemia, 418
330-332 Alpha-fetoprotein, in congenital anomaly
Acidosis, umbilical blood sampling in, 70- diagnosis, 541-542, 544
71 Alveofact. See SF-RI 1.
Acquired immunodeficiency syndrome. See Alveolar capillary dysplasia, 131
Human immunodeficiency virus infection. Alveolar-arterial oxygen gradient, in
Addiction, to cocaine. See Cocaine use. pulmonary hypertension, 133
Addiction Severity Index, 35 Amniocentesis, in isoimmune hemolytic
Adenosine deaminase deficiency, gene disease, 62
therapy in, 163-164 Amniotic fluid, in diabetic pregnancies,
Adrenal gland, fetal, in labor initiation, 9- prostaglandins in, 639-640
16 volume of, 553
Adrenocorticotropic hormone, fetal, in meconium in, as asphyxia indicator, 328-
labor initiation, 9-14 329
Adult respiratory distress syndrome. See surfactant extract from, 713, 817
Respiratory distress syndrome (adult). in respiratory distress syndrome (neo-
AIDS. See Human immunodeficiency virus natal), 725-726
infection. in established disease, 719
831
832 CUMULATIVE INDEX 1993
Amniotic fluid (Continued) Atrial flutter/fibrillation, umbilical blood
prophylactic, 716-718 sampling in, 72-73
Androstenedione, fetal, labor initiation Atrioventricular dissociation, congenital,
and, 15-16 93-94
Anemia, in diabetic nephropathy, 563, 567 Auditory brain stem evoked potentials, in
isoimmune hemolytic, erythropoietin perinatal asphyxia, 469-470
therapy in, 179-180 Autoimmune disease, maternal, congenital
umbilical blood sampling in, 61-65 heart block in, 93
of prematurity, 169-191 Azathioprine, in heart transplantation, 151-
erythropoietin therapy in, 183-186 152
normal erythropoiesis and, 170-173 Azidothymidine, in HIV infection, in
pathophysiology of, 174-176 pregnancy, 48-53
Anencephaly, pregnancy length in, 14-16
Animal models, of adult respiratory
distress syndrome, 769-773
of gene transfer, 160-165 Bacterial pneumonia, surfactants in, 775-
of hypoxic-ischemic encephalopathy, 776
359-363 Balance, Wilhelmy-Langmuir, in surfactant
of labor, primates as, 14-17 surface tension measurement, 669-671
sheep as, 9-14 Base excess, in perinatal asphyxia, 291
of perinatal asphyxia, magnetic reso- Beractant (Survanta), development of, 713
nance spectroscopy studies of, 359- in respiratory distress syndrome (neona-
363 tal), in animal studies, 818-821
in established disease, 720-721
visual evoked potentials and, 454
prophylactic, 716-718
of respiratory distress syndrome (neona-
Bergman’s minimal model estimation of
tal), surfactant therapy in, 714-715
insulin sensitivity, in gestational
of surfactant metabolism, 690-692
diabetes, 587-588
Antiarrhythmic drugs, in fetal
in pregnancy, 585-586
tachyarrhythmias, 73
Bernard-Soulier syndrome, umbilical blood
Antibacterial activity, of surfactant, 763,
765 sampling in, 67
Beta cell dysfunction, in gestational
Antibiotics, for intrauterine device diabetes, 603-604
insertion, 658 Birth asphyxia. See Perinatal asphyxia.
Antibodies, to lung, surfactant depletion Blackfan-Diamond syndrome,
from, 771-772
erythropoietin in, 174
Antiendotoxin antibody, in streptococcal Bleomycin, pulmonary fibrosis induced by,
infections, 219-220 surfactant therapy in, 779
Anti-inflammatory activity, of surfactant, Blood flow, cerebral, near infrared
765 spectroscopic quantification of, 371-
Antioxidants, in cerebral hypoxia-ischemia, 372
417-419 Blood sampling, umbilical. See Umbilical
Aortic valve, atresia of, in hypoplastic left- blood sampling.
heart syndrome, 145 Blood volume, cerebral, near infrared
Apgar scores, in perinatal asphyxia, 294— spectroscopic quantification of, 372
296, 330 Bovine spongiform encephalitis,
Apnea, recurrent, in surfactant therapy, 750 transmission of, in surfactant therapy,
Arachidonic acid deficiency, congenital 729-730
anomalies in, 522, 528 Bradycardia, fetal, delivery route for, 93
ARDS. See Respiratory distress syndrome Brain, blood flow in, near infrared
(adult). spectroscopic quantification of, 371-
Arm ergometry, in gestational diabetes, 372
627-628 blood volume of, near infrared spectro-
Artificial lung expanding compound, 818 scopic quantification of, 372
in respiratory distress syndrome (neona- computed tomography of, in asphyxia,
tal), 738-739 380-381
Asphyxia, perinatal. See Perinatal asphyxia. edema of, after asphyxia, 316
Aspiration pneumonia, surfactants in, 775 glucose metabolism in, PET studies of,
Asthma, surfactants in, 779-780 396-399
CUMULATIVE INDEX 1993 833
hemorrhage of, in surfactant therapy, 730 in animal studies, 818-821
in thrombocytopenic disorders, 65-67 prophylactic, 716-717
SPECT in, 388-389 Captive bubble method, in surfactant
hypoxic injury of. See also Hypoxic-ische- surface tension measurement, 672-682
mic encephalopathy. Cardiomyopathy, hypertrophic, in infant of
irreversible, 312 diabetic mother, 637
near infrared spectroscopy of, 369-378 Cardiovascular disorders, fetal /neonatal, in
infarction in, after asphyxia, 314-315 diabetic pregnancies, 519, 637
SPECT in, 388-389 maternal, in oral contraceptive use, 652
normal maturation of, magnetic reso- Cardiovascular system, cocaine effects on,
nance imaging of, 348-351 249
magnetic resonance spectroscopy in, Cardiovascular training, in gestational
355 diabetes, 627-628
nuclear magnetic resonance examination Catalase, in cerebral hypoxia-ischemia,
of. See Nuclear magnetic resonance 417-418
technology, in perinatal asphyxia. Central nervous system. See also Brain.
ultrasonography of, in asphyxia, 380 cocaine effects on, 249
Brain scan, in asphyxia, 382-383 congenital anomalies of, in diabetic preg-
Breast milk. See Milk, human. nancies, 518-519
Breastfeeding, 225-243 Cerebral blood flow, near infrared
infection transmission in, bacterial, 235- spectroscopic quantification of, 371—
236 372
cytomegalovirus, 232-233 Cerebral blood volume, near infrared
Epstein-Barr virus, 234-235 spectroscopic quantification of, 372
from mastitis, 236 Cerebral palsy, perinatal asphyxia and,
from skin lesions, 236 288-289, 488
hepatitis B, 233-234 PET studies of, 401-407
herpes simplex virus, 234 Cervix, dilatation of, biologic factors
HIV, evidence for, 230-232 regulating, 21
in perinatal period, 229-230 Cesarean section, in congenital anomalies.
worldwide perspective of, 228-229 See Delivery route, in congenital
human T lymphotropic virus type 1, anomalies.
233 indications for, in diabetic pregnancy,
mechanisms for, 227-228 558
proving, 228 Child abuse, in cocaine use, 256-257
rubella, 234 Chlorpropamide, in gestational diabetes,
toxoplasmosis, 236 606-607
trichinosis, 237 Cholesterol levels, aral contraceptive effects
tuberculosis, 236 on, 651-652
protective effects of, 225-227 Choreoathetosis, PET studies of, 404, 406
Breathing, fetal, in diabetic pregnancy, 553 Chromophores, in brain tissue, near
Bronchial smooth muscle, surfactant effects infrared spectroscopy of, 370
on, 765-766 Ciliary activity, in lung, surfactant effects
Bronchitis, chronic, surfactants in, 781 on, 763
Bronchopulmonary dysplasia, in surfactant CLSE. See Calf lung surfactant extract.
therapy of RDS, 724, 726, 751-752 Cocaine use, in pregnancy, 29-45, 245-262
administration routes for, 30
as chronic illness, 29-30
assessment of, 32-36
CAGE questionnaire, for substance abuse, continued in postnatal period, 254—257
34 drug combinations with, 257
Calcium channel blockers, in cerebral epidemiology of, 29
hypoxia-ischemia, 420-421 incidence of, 245-246
in hypertension, in diabetic nephropathy, indicators of, 33-34
567 mental health issues in, 31, 41, 255-256
Calf lung surfactant extract (Infrasurf), 818 neonatal effects of, birth outcomes
development of, 713 and, 250
in respiratory distress syndrome (neona- caregiving influences and, 254-257
tal), 725-726, 728 long-term, 253-254
834 CUMULATIVE INDEX 1993
Cocaine use (Continued) Corticosteroids, in heart transplantation,
neurobehavioral, 250-254 151-152
sensory motor developmental, 252- Corticotropin-releasing hormone, in labor
253 initiation, 10, 12
teratogenic, 248-250 Cortisol, fetal, in labor initiation, 9-14
obstetric complications from, 246-247 inhibition of, in lung maturation, 638
pharmacology of, 246-247 in insulin resistance, 622
professional attitudes toward, 32-33 CPHT (Exosurf, synthetic surfactant),
rehabilitation services for, 38-39 composition of, 697-698, 701
screening for, 32-36, 247-248 in respiratory distress syndrome (neona-
self-help groups for, 39 tal), 818
sexual victimization and, 40 adverse events from, 749-750
societal stigma for, 32 animal studies of, 820-821
sociodemographic factors in, 31-32 antenatal steroid prophylaxis and, 756
toxicology of, 35-36 controlled trials of, 739-741
treatment of, 36-41 dosage of, 754
Cognitive function, perinatal asphyxia in Open Study of Infants at high risk
effects on, 490 of/with Respiratory Insufficiency,
Colfosceril palmitate. See CPHT (synthetic 748-749
surfactant). in treatment investigational new drug
Colostrum, immunologic substances in, 227 program, 748
Compassionate care, in hypoplastic left- in very low birth weight infants, 756
heart syndrome, 152 long-term results of, 757
Computed tomography, in perinatal physiologic issues in, 752-753
asphyxia, 380-381 prophylactic, 741-743
Congenital anomalies, antenatal therapy of, vs. rescue approach, 754, 756
81-83 rescue trials with, 744-748, 754, 756
cocaine use and, 248-249 safety considerations with, 756-757
delivery route in. See under Delivery unmet expectation with, 750-752
route. vs. mammalian surfactants, 756
in conjoined twins, 97-99 metabolism of, 701-705
in diabetic pregnancies, 517-532, 533- surface tension of, 679-682
547, 635-636 Clq, surfactant protein A homology with,
clinical manifestations of, 518-520 793
diagnosis of, 541-544 Crack cocaine. See Cocaine use.
epidemiology of, 517-518 Crying, abnormalities in, from cocaine
etiology of, 520 exposure, 252
free oxygen radicals in, 526 Curosurf, development of, 713
genetic susceptibility and, 527 in respiratory distress syndrome (neona-
incidence of, 533-534 tal), 725, 729
maternal vasculopathy and, 519-520 prophylactic, 718
metabolic fuel alterations in, 533-537 Cyclosporine, in heart transplantation, 151-
common pathway for, 528 152
hyperglycemia, 520-523 Cystic fibrosis, surfactant therapy in, 777—
hyperketonemia, 523-524 779
hypoglycemia, 525 Cystic hygroma, delivery route for, 89-91
prenatal testing for, 541-544 Cytomegalovirus infection, transmission of,
prevention of, 528-530, 539-541 in breastfeeding, 232-233
somatomedin inhibitors in, 526-527 umbilical blood sampling in, 68-69
spontaneous abortion in, 537-538
zine deficiency and, 527
of heart, erythropoietin therapy in, 179
Contraception, for diabetic woman, 649- Deafness, in perinatal asphyxia, 488-489
661 Death, in surfactant therapy of RDS, 724-
intrauterine device, 656-658 726
oral, 650-655 intrauterine, in maternal diabetes, 549-
progestins, 655-656 551, 564-565
Contraction stress test, in diabetic Deferoxamine, in cerebral hypoxia-
pregnancy, 551-552 ischemia, 414-415
CUMULATIVE INDEX 1993 835
Dehydroepiandrosterone, fetal, labor preconception care in, 539-540
initiation and, 15-16 retinopathy in, 571-581
Delivery, in diabetic pregnancy, 557—558 infection in, from intrauterine device,
lung maturity assessment before, 639- 657-658
nephropathy in. See Diabetic nephropathy.
Delivery route, disease transmission and, preeclampsia in, 562-563
HIV infection, 229-230 intrauterine death and, 550
in congenital anomalies, 81-106 retinopathy in. See Diabetic retinopathy.
conjoined twins, 97-99 Diabetic embryopathy. See Congenital
cystic hygroma, 89-91 anomalies, in diabetic pregnancies.
heart block, 92-94 Diabetic nephropathy, in pregnancy, 561-
hydrocephalus, 87-89 570
meningomyelocele, 83-87 clinical features of, 561
monoamniotic twins, 97-99 incipient, 562-563
sacrococcygeal teratoma, 91-92 long-term effects of, 567-569
ventral wall defects, 94-97 overt, 563-564
Depo-medroxyprogesterone acetate, for perinatal outcome in, 564-566
diabetic woman, 656 treatment of, 566-567
Detergent aerosol, in surfactant disruption, Diabetic retinopathy, 571-581
770 classification of, 572-573
Dexamethasone, fetal administration of, in pregnancy, 571-572, 577-580
labor initiation and, 14, 16 incidence of, 571-572
Diabetes, gestational. See Gestational nonproliferative, 572
diabetes. pathophysiology of, 573-577
Diabetes mellitus, classification of, 514 proliferative, 572-573
contraception in, 649-661 treatment of, 572-573, 579-580
insulin-dependent, 652-653 Diet, in diabetic nephropathy, 566-567
intrauterine device, 656-658 in gestational diabetes, 605-606, 629-631
non-insulin dependent, 655 Dimethylthiourea, in cerebral hypoxia-
oral, 650-655 ischemia, 418
progestins, 655-656 Dipalmitoyl phosphatidylcholine, in
control of, in nephropathy, 566-567 surfactants, natural, 737-738, 815
in pregnancy, 539-540 synthetic, metabolism of, 699-704
congenital anomaly rate and, 528- synthetic, in respiratory distress syn-
529 drome (neonatal), 738
in retinopathy, 579 Dipalmitoyl phosphatidylcholine-
in offsprings of diabetic mothers, 644 phosphatidylglycerol mixtures, in
in pregnancy, congenital anomalies respiratory distress syndrome
caused by. See Congenital anomalies, (neonatal), 738-739
in diabetic pregnancies. Diplegia, spastic, PET studies of, 402-403
control of, 539-540 Discriminant function analysis, in risk
congenital anomaly rate and, 528— scoring for preterm birth, 109
529 Dopamine, in pulmonary hypertension, 136
fetal growth evaluation in, 542-543 Doppler studies, in fetal surveillance, in
fetal surveillance in, 549-560 diabetic pregnancy, 554-555
contraction stress test in, 551-552 Down syndrome, incidence of, in diabetic
delivery timing and route in, 557- pregnancies, 542
558 Drug abuse, cocaine in. See Cocaine use.
Doppler studies in, 554-555 Drug Abuse Screening Test, 34-35
fetal biophysical profile in, 552-553 Ductus arteriosus, patency of, in
maternal assessment in, 553-554 hypoplastic left-heart syndrome,
nonstress test in, 552 147-148
programs for, 555-556 in surfactant therapy, 723, 727, 750
historical review of, 507-515
infant morbidity in. See Infants of dia-
betic mothers.
intrauterine death in, 549-551, 564-565 Echocardiography, in pulmonary
nephropathy in, 561-570 hypertension, 132
outcome of, 507-508, 512-515 Edema, brain, after asphyxia, 316
836 CUMULATIVE INDEX 1993
Edema (Continued) Fetal monitoring, electronic, as predictor of
pulmonary, surfactant effects on, 762- asphyxia, 293-294
763 Fetus, congenital anomalies of, antenatal
Embryopathy, diabetic. See Congenital therapy of, 81-83
anomalies, in diabetic pregnancies. erythropoiesis in, 170-172
Encephalitis, transmission of, in surfactant growth of, in diabetic pregnancy, 565-
therapy, 729-730 566
Encephalocele, delivery route for, 84 evaluation of, 542-543
Encephalopathy, hypoxic-ischemic. See in gestational diabetes, 611-613
Hypoxic-ischemic encephalopathy. in large for gestational age infants,
Endotoxin, antibody to, in streptococcal 636-637
infections, 219-220 in small for gestational age infants,
Enhérning pulsating-bubble surfactometer, 637-638
in surfactant surface tension hypothalamic-hypophyseal-adrenal axis
measurement, 671-672 of, in labor initiation, 9-14
Enteral feeding, of low birth weight infant, of diabetic mother, breathing movements
advancement of, 197-198 of, 553
hypocaloric, 198 growth of, 542-543, 565-566
initiation of, 197-198 intrauterine death of, 549-551, 564-565
Epstein-Barr virus, transmission of, in malformations in. See Congenital anom-
breastfeeding, 234-235 alies.
Ergometer training, in gestational diabetes, movement of, 553-554
627-628 surveillance of, 549-560
Erythropoiesis, in fetus, 170-172 contraction stress test in, 551-552
Doppler studies in, 554-555
Erythropoietin, adverse effects of, 177
in anemia of prematurity, 169-191 fetal biophysical profile in, 552-553
biology of, 172-173 in gestational diabetes, 556-557
lung maturity evaluation in, 558
levels of, 174-176
maternal assessment in, 553-554
normal erythropoiesis and, 170-173
nonstress test in, 552
treatment with, 183-186
programs for, 555-556
in congenital heart disease, 179
tone of, 553
in end-stage kidney disease, 176-178 small for gestational age, umbilical blood
in isoimmune hemolytic anemia, 179
sampling in, 70-71
Estrogens, anti-insulin properties of, 622 thrombocytopenic disorders in, umbilical
in oral contraceptives, for diabetic blood sampling in, 65-67
woman, 650-651 transition to neonatal circulation in, pul-
placental, labor initiation and, 13-15, monary hypertension and, 128-131
18-20 umbilical blood sampling in. See Umbili-
Euglycemic clamp technique, in insulin cal blood sampling.
sensitivity assessment, in gestational Fibrosis, pulmonary, surfactants in, 779
diabetes, 588 Fluid dispersal, in lung, surfactant effects
in pregnancy, 585-586 on, 763
Evoked potentials, in asphyxia, auditory Flunarizine, in cerebral hypoxia-ischemia,
brain stem, 469-470 421
somatosensory, 458-459, 463-482 Folic acid supplementation, in diabetic
visual, 451-461, 470-471 pregnancies, 540-541
Exercise, in gestational diabetes, 606, 624— Fontan procedure, in hypoplastic left-heart
629 syndrome, 149-150
Exosurf. See CPHT (synthetic surfactant). Free radicals, in diabetic embryopathy, 526,
Extracorporeal membrane oxygenation, in 528
pulmonary hypertension, 137-139 inhibitors/scavengers of, in hypoxic-
SPECT in, 388-389 ischemic encephalopathy, 412-419
release of, after perinatal asphyxia, 313
Failure to thrive, maternal cocaine use and,
256-257 Gastrointestinal system, congenital
Fetal biophysical profile, in diabetic anomalies of, in diabetic pregnancies,
pregnancy, 552-553 519
CUMULATIVE INDEX 1993 837
Gastroschisis, delivery route for, 94-97 Glibenclamide, in gestational diabetes, 631
Gaucher's disease, gene therapy in, 164— Glomerular filtration rate, in diabetic
165 nephropathy, 563
Gavage feeding, of low birth weight Glucagon levels, in gestational diabetes,
infants, 203-204 587
Gene transfer, into hematopoietic cells, in pregnancy, 585
155-168 Glucocerebrosidase deficiency, gene
animal models for, 160-165 therapy in, 164-165
indications for, 163-165 Glucose, absorption of, diet effects on, 605
modalities for, 156-160 cerebral, PET studies of, 396-399
Moloney murine leukemia virus in, role in hypoxic-ischemic encephalopa-
156 thy, 421-423
packaging cell lines in, 157-159 levels of. See also Hyperglycemia; Hypo-
safety issues in, 162-163 glycemia.
target cells for, 159-160 determination of, strip tests in, 640
vector construction in, 156-157 exercise effects on, 624
Genetic factors, in diabetic embryopathy, in diabetic pregnancies, congenital
527 anomalies and, 520-523, 525-526,
Genetically engineered surfactants, 791-811 528-529
in respiratory distress syndrome, animal in gestational diabetes, 587
studies of, 804-808 in normal pregnancy, 584-585
surfactant protein characteristics and, metabolism of, 574-575
792-804 oral contraceptive effects on, 651
Gestational age, perinatal asphyxia and, Glucose tolerance test, in gestational
309-310 diabetes, for diagnosis, 596-600
Gestational diabetes, 603-617, 619-634 for screening, 595-596
complications of, 611-613 Glutamate toxicity, in cerebral hypoxia-
contraception in, 654-655 ischemia, 419-420
diagnosis of, 584, 593-602 Glyburide, in gestational diabetes, 606-607
glucose tolerance test in, 597-600 Glycohemoglobin, in diabetic pregnancies,
screening tests for, 593-597 congenital anomaly rate and, 535-
fetal surveillance in, 556-557 537
glucagon levels in, 587 spontaneous abortion rate and, 537-—
glucose levels in, 587 538
in obese patients, 605-606 vs. alpha-fetoprotein levels, 542
incidence of, 619 Glypizide, in gestational diabetes, 607
insulin levels in, 587 Graves’ disease, maternal, umbilical blood
insulin release in, 588-589 sampling in, 72
insulin sensitivity in, 587-588 Growth, fetal, in diabetic pregnancy, 565-
ketonuria in, 629-630 566
lipid levels in, 587 evaluation of, 542-543
management of, 605-613 in gestational diabetes, 611-613
diet in, 605-606, 629-631 in large for gestational age infants,
exercise in, 606, 624-629 636-637
insulin in, 607-610, 613 in small for gestational age infants,
optimum glucose levels in, 610-613 637-638
oral hypoglycemic agents in, 606-608, retardation of, susceptibility to perina-
631 tal asphyxia in, 310-311
metabolic changes in, 583-591 perinatal asphyxia effects on, 489
offspring diabetes mellitus development
and, 644
pathogenesis of, 603-605
pathophysiology of, 620-623 Handicapped infants, very low birth
risk factors for, 594-595, 619-620 weight, prevalence of, 263-277
screening for, 594-597 Head circumference, cocaine use and, 250
reasons for, 593-594 Heart, congenital disease of, erythropoietin
vs. diabetes mellitus, 583 therapy in, 179
Glenn anastomosis, in hypoplastic left- hypoplastic. See Hypoplastic left-heart syn-
heart syndrome, 149-150 drome.
838 CUMULATIVE INDEX 1993
Heart (Continued) Human somatomammotropin, metabolic
transplantation of, in hypoplastic left- effects of, 623
heart syndrome, 150-151 Human T lymphotropic virus type 1,
Heart block, congenital, delivery route for, transmission of, in breastfeeding, 233
92-94 Hydrocephalus, antenatal treatment of, 89
Heart rate, fetal, as asphyxia indicator, delivery route for, 87-89
329-330 Hydrogen peroxide formation, prevention
HEAT questionnaire, for substance abuse, of, in cerebral hypoxia-ischemia, 413-
34 414
Hematopoietic cells, gene transfer into. See B-Hydroxybutyrate levels, in diabetic
under Gene transfer. pregnancies, congenital anomalies and,
Hemiplegia, spastic, PET studies of, 403- 523
404 Hyperbilirubinemia, asphyxia-related
Hemoglobin, vs. erythropoietin, 174 neurotoxicity and, 362-363
Hemoglobin A1C, in diabetic pregnancies, Hyperglycemia, in diabetic pregnancies,
congenital anomaly rate and, 535- congenital anomalies and, 520-523,
537 528-529
spontaneous abortion rate and, 537- intrauterine death and, 550
538 protective role of, in hypoxic-ischemic
vs. alpha-fetoprotein levels, 542 encephalopathy, 422-423
Hemolysis, isoimmune, erythropoietin retinopathy in, 573
therapy in, 179-180 Hyperimmune immunoglobulin therapy, in
umbilical blood sampling in, 61-65 infections, 218-221
Hemorrhage, intracranial, in surfactant Hyperinsulinemia, fetal, intrauterine death
therapy, 730 and, 550-551
in thrombocytopenic disorders, 65-67 lung maturation and, 638-639
intraventricular, after asphyxia, 317 macrosomia and, 636-637
in surfactant therapy of RDS, 723-724 neonatal hypoglycemia and, 641
pulmonary, in surfactant therapy, 730, Hyperketonemia, in diabetic pregnancies,
749-750 congenital anomalies and, 523-524
Hepatitis B, transmission of, 729 Hypertension, in diabetic nephropathy,
in breastfeeding, 233-234 563-564
Herpes simplex virus, transmission of, in control of, 567
breastfeeding, 234 persistent pulmonary. See Persistent pul-
Hexadecanol, in synthetic surfactant. See monary hypertension.
also CPHT (synthetic surfactant). Hyperthyroidism, umbilical blood
metabolism of, 702 sampling in, 71-72
HIV infection. See Human immunodeficiency Hyperventilation, therapeutic, in
virus infection. pulmonary hypertension, 134-135, 139
Hormones, in gestational diabetes, 621-622 Hyperventilation/hyperoxia test, in
Human immunodeficiency virus infection, pulmonary hypertension, 132
cocaine use and, 246-247 Hypocalcemia, in infant of diabetic mother,
in pregnancy, 49-60 642-643
anti-Pneumocystis therapy in, 48, 51, Hypoglycemia, in diabetic pregnancies,
53-54 congenital anomalies and, 525-526
antiviral drugs in, 48-53 in infant of diabetic mother, 640-642
immunotherapy in, 54-56 Hypoglycemic agents, oral, in gestational
pneumonia with, surfactants in, 776 diabetes, 606-608, 631
screening for, in human milk banking, Hypomagnesemia, in infant of diabetic
202 mother, 643
transmission of, in breastfeeding, evi- Hypoplastic left-heart syndrome, 145-154
dence for, 230-232 anatomy of, 145-146
worldwide perspective of, 228-229 anomalies associated with, 146
in delivery, 229-230 cardiac transplantation in, 150-152
in perinatal period, 229-232 compassionate care in, 152
vertical, 229-230 genetic predisposition to, 146-147
azidothymidine effects on, 48-49 Norwood operation in, 149-150
immunotherapy effects on, 54-56 pathophysiology of, 147-148
umbilical blood sampling in, 70 preoperative management of, 148-149
CUMULATIVE INDEX 1993 839
prevalence of, 146 Immunologic substances, in human milk,
Hypothalamic-hypophyseal-adrenal axis, 225-227
fetal, in labor initiation, 9-16 Immunosuppressive therapy, in heart
Hypothermia, in hypoxic-ischemic transplantation, 151-152
encephalopathy, 423-425 Immunotherapy, in HIV infection, in
Hypothyroidism, umbilical blood sampling pregnancy, 54-56
in, 71-72 in thrombocytopenic disorders, 67
Hypoxemia, in pulmonary hypertension, Infants of diabetic mothers, 635-646
131-133 complications in, 643-644
repetitive, pathophysiology of, 310 congenital anomalies in. See Congenital
Hypoxia, fetal, in maternal diabetes, 550 anomalies.
respiratory distress syndrome treatment diabetes mellitus development in, 644
response and, 727 growth disorders in, large for gestational
umbilical blood sampling in, 70-71 age, 636-637
Hypoxic-ischemic encephalopathy, 296 small for gestational age, 637-638
academic function in, 490-491 hypocalcemia in, 642-643
animal models of, 359-363 hypoglycemia in, 640-642
categories of, 484-488 hypomagnesemia in, 643
cerebral palsy and, 488 intellectual performance in, 643-644
cognitive ability effects of, 490 pulmonary development in, 638-640
computed tomography in, 380-381 Infarction, brain, after asphyxia, 314-315
damage mechanisms after, 311-318 Infections, congenital, umbilical blood
deafness in, 488-489 sampling in, 67-70
factors influencing outcome in, 309-311 from intrauterine device, 657-658
growth effects of, 489 immunoglobulin therapy in, 211-223
magnetic resonance imaging in, 351-352 antiendotoxin antibody in, 219-220
magnetic resonance spectroscopy in, as treatment, 212-215
355-356 hyperimmune type, 218-221
near infrared spectroscopy in, 369-378 prophylactic, 215-218
neuropsychologic effects of, 491-495 streptococcal, 218-219
PET studies of, 399, 401 transmission of, in breastfeeding. See
radionuclide brain scan in, 382-383 under Breastfeeding.
sonography in, 380 in surfactant therapy, 729-730
SPECT in, 386-392 Inflammation, surfactant reduction of, 765
therapy for, 411-432 Influenza, pneumonia in, surfactants in,
calcium channel blockers in, 420-421 775
excitatory amino acid antagonists in, Infrasurf. See Calf lung surfactant extract.
419-420 Insulin, action of, 574
free radical inhibitors/scavengers in, early clinical trials‘of, 508-512
412-419 estrogen antagonism of, 622
hypothermia in, 423-425 in gestational diabetes, 607-610, 613
primary preventive, 413-416 levels of, in gestational diabetes, 587
secondary interventional, 417-419 in pregnancy, 584-585
substrate availability considerations in, pulmonary surfactant synthesis and,
421-433 638-639
release of, in gestational diabetes, 588—
589
in pregnancy, 586
Immune response, to surfactant therapy, resistance to, in gestational diabetes,
730 604-605, 620
Immunoglobulin(s), as formula additives, sensitivity to, in gestational diabetes,
203 587-588
in human milk, 225-227 in pregnancy, 585-586
intravenous, in infections, 211-223 teratogenic testing of, 527-528
antiendotoxin antibody in, 219-220 Intracranial hemorrhage, in surfactant
as treatment, 212-215 therapy, 730
hyperimmune type, 218-221 in thrombocytopenic disorders, 65-67
prophylactic, 215-218 Intrauterine death, in diabetic
streptococcal, 218-219 nephropathy, 564-565
840 CUMULATIVE INDEX 1993
Intrauterine death (Continued) Left heart hypoplasia. See Hypoplastic left-
in maternal diabetes, 549-551 heart syndrome.
Intrauterine device, for diabetic woman, Levonorgestrel, in oral contraceptives, 651
656-658 Lipid levels, in gestational diabetes, 587
Intravenous glucose tolerance test, in in pregnancy, 584
gestational diabetes, 597, 600 oral contraceptive effects on, 651-652
Intraventricular hemorrhage, after Lipid peroxidation, diabetic embryopathy
asphyxia, 317 and, 526, 528
in surfactant therapy of RDS, 723-724 Lipid-extract surfactant, surface tension of,
Iron elimination, in cerebral hypoxia- 675, 677
ischemia, 414—415 Liver, erythropoietin production in, 172-
Isoimmunization, red blood cell, 173
erythropoietin therapy in, 179-180
Logistic regression, in risk scoring for
umbilical blood sampling in, 61-65
preterm birth, 110
Low birth weight infants, handicapped,
prevalence of, 263-277
head circumference of, 250
Kell antibodies, umbilical blood sampling
nutrition in. See under Nutrition.
for, 62-63
Lung. See also Pulmonary.
Ketoacidosis, in pregnancy, intrauterine
death and, 550 antibodies to, surfactant depletion from,
771-772
treatment of, 512
Ketones, in diabetic pregnancies, congenital microstructure of, surfactant surface ten-
anomalies and, 523-524 sion effects on, 669
in gestational diabetes, 629-630 transplantation, surfactants in, 776-777
Kidney, diabetic involvement of. See Lung maturity, fetal, in diabetic pregnancy,
Diabetic nephropathy. 638-640
erythropoietin production in, 172-173 evaluation of, 558
failure of, erythropoietin therapy in, 176- Lymphocytes, in human milk, 227
178 Lysophospholipids, antibacterial activity of,
765
Labor, biologic basis of, 9-27
cervical dilatation in, 21 Macrophages, in human milk, 227
contracture-to-contraction switch in, Macrosomia, in diabetes mellitus, 636-637
20-21
in gestational diabetes, pathophysiology
fetal hypothalamic-hypophyseal-adre-
of, 611-612
nal axis in, 9-13 prevention of, 613
in preterm labor, 21-22
Magnetic resonance imaging, 346-353
in primates, 14-17
fundamentals of, 346-348
in sheep, 9-14
in asphyxia, 351-352
myometrial activity in, 17-22
timing of, vs. neurodevelopmental out-
placental events in, 13-14
come, 352-353
prostaglandins in, 13-14, 21
normal brain maturation and, 348-351
response to oxytocin and, 20
Malformations, congenital. See Congenital
stressors in, 22
cerebral oxygenation assessment during, anomalies.
375-376 Mannose-binding proteins, surfactant
Large for gestational age infants, maternal protein A homology with, 793-794
diabetes and, 636-637 Mastitis, breastfeeding with, 236
La/SSB autoantibodies, congenital heart May-Hegglin anomaly, umbilical blood
block and, 93 sampling in, 67
Lavage, in surfactant depletion, 771 Mechanical ventilation, in pulmonary
Lazeroids, in cerebral hypoxia-ischemia, hypertension, 134-135
418 surfactant therapy with, 730, 750-752
Lecithin/sphingomyelin ratio, in diabetic Meconium aspiration syndrome,
pregnancy, 558, 639-640 surfactants in, 777
surfactant therapy effects on, 692-693 Meconium staining, in asphyxia, 328-329